 |
|
|
| |
Establishment of persistent functional remission of HBV and HDV infection following REP 2139-Ca and pegylated interferon alpha-2a therapy in patients with chronic HBV / HDV co-infection: 1.5 -2 year follow-up results from the REP 301-LTF study
|
| |
| |
Reported by Jules Levin
EASL 2018 April 11-15 Paris France
M. Bazinet1, V. Pantea2, V. Cebotarescu2, L. Cojuhari2, P. Jimbei3, A. Krawczyk4, A. Vaillant1
1.Replicor Inc. Montreal, Canada
2.Department of Infectious Diseases, Nicolae TestemitanuState University of Medicine and Pharmacy, Chisinau, Republic of Moldova
3.TomaCiorbaInfectious Clinical Hospital, Chisinau, Republic of Moldova.
4.UniversitätsklinikumEssen, Institute for Virology, Essen, Germany.
|
| |
|
|
|
|
|
